EBITDA Margin % is calculated as EBITDA divided by its Revenue. Roivant Sciences's EBITDA for the
three
months ended in Mar. 2026 was €-306.52 Mil. Roivant Sciences's Revenue for the
three
months ended in Mar. 2026 was €2.18 Mil. Therefore, Roivant Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was -14,060.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Roivant Sciences EBITDA Margin % Related Terms
Roivant Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:87S vs INSM, INCY, BNTX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Roivant Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (FRA:87S) has a EBITDA Margin % of -14,060.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #894 out of 945 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Roivant Sciences' EBITDA Margin % too high?
Roivant Sciences' current EBITDA Margin % is -14,060.50%. Based on the distribution chart, Roivant Sciences ranks #894 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' EBITDA Margin % compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #894 out of 945 companies for EBITDA Margin %. This places Roivant Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current EBITDA Margin % is -14,060.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.56, compared to a current price of €30.01 — trading 250.6% above its estimated fair value. The current EBITDA Margin % is -14,060.50%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current EBITDA Margin % is -14,060.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (FRA:87S) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of €30.01 is trading 250.6% above its estimated GF Value™ of €8.56.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for FRA:87S:
EBITDA Margin %: -14,060.50%
GF Value™: €8.56 vs. price of €30.01 (250.6% above fair value)
No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for FRA:87S
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87S has been successfully added to your 
